Announcements Trials
Browse Landscape

Phase

Phase 2 19Phase 4 2Phase 3 2Phase 1 2Phase 1/2 1

Status

Unknown 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 44Gastrointestinal 3Thoracic 2Lymphoid 2Genitourinary 2Other hematologic neoplasm 1Gynecologic 1CNS 1

Conditions

Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Extranodal NK-T-Cell 1

Interventions

Rituximab 238Cyclophosphamide 192Vincristine 164Doxorubicin 150Prednisone 126Methotrexate 80Cytarabine 79Etoposide 78Dexamethasone 72Radiotherapy 60Bendamustine Hydrochloride 58Mercaptopurine 46Lenalidomide 42pegaspargase 41Prednisolone 38Filgrastim 38ibrutinib 37fludarabine 36Bleomycin 36Daunorubicin 35obinutuzumab 34Asparaginase 33Leucovorin 29venetoclax 28Granulocyte Colony-Stimulating Factor 28Chlorambucil 27Calcium Dobesilate 27Gemcitabine 26Vinblastine 25Thioguanine 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Thalidomide × Lymphoid × Clear all
NCT02085655 2021-03-15

PEG-ASP+Gemox Regimen and Thalidomide for NK/T Lymphoma

Sun Yat-sen University

Phase 3 Unknown
264 enrolled
Lymphoid

Lymphoma, Extranodal NK-T-Cell

NCT03016000 2017-07-28

Thalidomide Maintenance Treatment in DLBCL

Nanfang Hospital, Southern Medical University

Phase 3 Unknown
226 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡